Breaking News

‘Groundhog Day’ drug shortages, Lilly’s bold push into the obesity drug race, and controversy in the world of ‘synthetic embryos’

June 28, 2023

Good morning. I'm chronic disease reporter Isa Cueto, filling in for Liz today. It's midweek, and we're all in need of a refresher — STAT's homepage included. Check out our new look (and new shade of teal), and read more about the redesign from our executive editor.

Cancer

Cancer drug shortage is 'like Groundhog Day'

The current cancer drug shortage started with the shutdown of a massive pharma plant near Ahmedabad, India, which produced over half the U.S. supply of a crucial chemotherapy. Now, hospitals are in a crunch to find therapies their cancer patients need. It's a frustratingly familiar story to providers who feel like they're living "Groundhog Day." Drug shortages, even of commonly used generics, antibiotics, and off-patent therapies, have plagued health care for over a decade. 

"It's not even the new normal. It's the normal," said Yoram Unguru, a pediatric hematologist oncologist who has struggled over the past decade to get treatments his patients need. Many say shortages are a completely preventable crisis with commonsense solutions. But getting hospitals and drugmakers on board is the challenge. STAT's Angus Chen has more.


obesity

Lilly gains steam in competitive obesity drug market

AdobeStock_367358058-768x432
Adobe

STAT's Elaine Chen has been on the West Coast at the American Diabetes Association conference in San Diego this week, where the race to develop a new generation of obesity drugs has been on full display. And while Novo Nordisk has become a dominant player with the now-ubiquitous Ozempic and Wegovy, Eli Lilly looks to be gaining an edge. 

This past weekend, Lilly dropped results from a slew of successful trials, including an effective pill and an injectable that showed the most weight loss of any obesity drug to date — 24% of body weight. "Most of the other [big] companies — they gotta be probably a little bit worried," Raymond Stevens, CEO of Structure Therapeutics, told Elaine. With global sales of obesity drugs estimated to reach $30 billion by 2030, drugmakers are expected to stay in hot competition. Read more.


mental health

Childhood cancer survivors at higher risk of mental health issues

Advances in medicine have made children's chances of surviving cancer greater than ever before. But survivors are at a higher risk of long-term mental health consequences than their peers, according to a recent meta-analysis published in JAMA Pediatrics. The analysis of 52 clinical studies including over 20,000 cancer survivors looked at the prevalence and severity of psychological disorders. 

Researchers found that childhood, adolescent, and young adult cancer survivors were 57% more likely to develop depression, 29% more likely to develop anxiety, and 56% more likely to develop psychotic disorders in the years following treatment compared to their siblings or healthy members of a control group. While later-in-life chronic conditions are pretty well-documented in these patients, the psychological and psychiatric toll of childhood cancer is less understood, STAT's Bree Iskandar reports



Closer Look

'Synthetic embryos,' real beef: Stem cell research is in the midst of a chaotic coming out party

Scientists creating so-called synthetic embryos in hopes of unlocking the secrets of early human development are getting more attention than they might've bargained for. Between heated competition that boiled over at a meeting earlier this month, overhyped press, and public blowback, some worry too many eyes on the field will lead to a regulatory crackdown. STAT's Megan Molteni describes it as "exactly the kind of chaotic coming out party the still-small but expanding field had hoped to avoid." 

This week, the International Society for Stem Cell Research even urged researchers to move away from the term synthetic embryos altogether, emphasizing that the clumps of cells can't develop into fully formed humans. And the hope is that these models could elucidate more than just embryo growth — potentially helping to demystify miscarriage and infertility, or to make organs and tissues for transplantation. Read more. 


research

Scientists find clues about brain chemicals underpinning OCD behaviors

Compulsive and habitual behaviors, which are common in people with obsessive-compulsive disorder and other conditions, might have neurochemical underpinnings. In a small study published yesterday in Nature Communications, researchers found a link between compulsivity and certain neurotransmitters.

The study of 61 people, half with OCD, suggests a relationship between the neurotransmitter glutamate, which excitedly passes messages along, and the calming GABA neurotransmitter (which blocks certain messages to the central nervous system). When the interaction becomes unbalanced, it might feed into harmful levels of compulsive behavior. Both groups of participants exhibited this dynamic in a brain region that controls movement, meaning compulsivity might be a "universal phenomenon" in parts of the brain. But researchers found that those with OCD might also have a push-and-pull between glutamate and GABA in the anterior cingulate cortex, which plays a role in cognitive and emotional processing.


long Covid

WHO: 36 million people in Europe have experienced long Covid

Over three years into the pandemic, we still don't know a lot about long Covid. Estimates of long Covid prevalence have varied widely, blurring the true impact on a population's health. Yet the burden of long Covid on those who struggle with the condition has become clear. In Europe, approximately 36 million people have experienced long Covid since 2020, Hans Henri P. Kluge, WHO regional director for Europe, said yesterday

Kluge cited data from the Institute for Health Metrics and Evaluation at the University of Washington in Seattle, which suggests nearly 1 in 30 people across 53 countries in the WHO European Region may have experienced long Covid in the first three years of the pandemic. The staggering numbers are more than double what WHO officials said last September, when they estimated at least 17 million Europeans had experienced long Covid in the first two years of the pandemic.


On this week's episode of the "First Opinion Podcast," STAT's Torie Bosch chats with oncologist Kristen Rice about the shortages of lifesaving cancer drugs that have been happening for several years but have been progressively worsening in the past few months. Listen now.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • North Carolina was an abortion haven. With its new 12-week ban, the protection will vanish, The 19th
  • Landmark study shows higher suicide risk for transgender people, New York Times
  • FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines, STAT
  • Malaria cases in Florida, Texas are first US spread in 20 years, CDC warns, CNN
  • Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit, STAT
  • Janitor cut power to lab freezer, destroying $1M of research, suit alleges, Washington Post

Thanks for reading, more tomorrow! — Isa

Isa Cueto is a chronic disease reporter at STAT.


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments